ArticleJournal of diabetes research2026
Long-Term Glycemic Control and Pharmacotherapy in Type 2 Diabetes Mellitus: A Descriptive Analysis of 10-Year Trends in a Statewide Sample.
Article in Journal of diabetes research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Long-Term Glycemic Control and Pharmacotherapy in Type 2 Diabetes Mellitus: A Descriptive Analysis of 10-Year Trends in a Statewide Sample.Journal of diabetes research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundLittle is known about prescribing and glycemic control trends for Type 2 diabetes (T2D) drug classes across populations.
objectiveThe aim of this study is to assess long-term glycemic control in a statewide sample prescribed with T2D drugs.
designDescriptive analysis of retrospective 10-year cohort data from the Indiana Health Information Exchange in the United States.
participantsAdults with T2D were prescribed at least one diabetes drug. MAIN MEASURES: Glycemic success is the number of A1c < 7% for age < 65 or <8% for age ≥65/(number of A1c tests) in any given year. Prescription rate is the number of subjects with a drug ordered in a year, divided by the population size in that year. >
resultsGlycemic success was 60%, with year-to-year changes of 0%-1%. The prevalence of glycemic success was greater for females (mean of 62%-64%) than males (57%-59%); participants aged 65 or above (75%-89%) versus younger patients (43%-62%); and White (61%-63%) versus Black (51%-54%) patients. Biguanides (56%-63%) were most frequently prescribed, followed by sulfonylureas (29%-33%) and fast-acting and long-acting insulins (30%-32%). Black participants had more insulin prescriptions (47%-50%, vs. non-Black, 9%-49%%). Newer drugs were more frequently prescribed for White than non-White patients: 10%-17% versus 1.3%-17% for dipeptidyl peptidase 4 inhibitors; < 1%-9% versus 0.2%-8% for sodium/glucose cotransporter 2 inhibitors; and 5.3%-12% versus 1%-12% for glucagon-like peptide receptor agonists. A greater number of diabetes drug classes ever prescribed was associated with lower glycemic success (1 class with 76%, vs. 2-3 classes with 55%, vs. 4-9 classes with 37%).
conclusionsGlycemic control did not substantively improve over a 10-year period, despite the availability of new medications. Racial minorities received fewer prescriptions for newer drugs. Future research should examine factors contributing to prescription pattern differences and barriers to glycemic control.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.